Premium
European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC
Author(s) -
Nast A.,
Spuls P.I.,
Kraaij G.,
Gisondi P.,
Paul C.,
Ormerod A.D.,
Saiag P.,
Smith C.H.,
Dauden E.,
Jong E.M.,
Feist E.,
Jobling R.,
Maccarone M.,
Mrowietz U.,
Papp K.A.,
Reich K.,
Rosumeck S.,
Talme T.,
Thio H.B.,
Kerkhof P.,
Werner R.N.,
Dressler C.
Publication year - 2017
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.14454
Subject(s) - secukinumab , ixekizumab , medicine , apremilast , venereology , dermatology , psoriasis , biosimilar , medline , randomized controlled trial , psoriatic arthritis , surgery , political science , law
European S3-Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC A. Nast,* P.I. Spuls, G. van der Kraaij, P. Gisondi, C. Paul, A.D. Ormerod, P. Saiag, C.H. Smith, E. Dauden, E.M. de Jong, E. Feist, R. Jobling, M. Maccarone, U. Mrowietz, K.A. Papp, K. Reich, S. Rosumeck, T. Talme, H.B. Thio, P. van de Kerkhof, R.N. Werner, C. Dressler